Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up

Yao, 2008, One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States, J Clin Oncol, 26, 3063, 10.1200/JCO.2007.15.4377

Rindi, 2011, Gastroenteropancreatic (neuro)endocrine neoplasms: the histology report, Dig Liver Dis, 43, S356, 10.1016/S1590-8658(11)60591-4

Hörsch, 2014, THERANOSTICS – Clinical aimshots in surgical warfare against neuroendocrine cancer, Ann Trans Med, 2, 1

Teunissen, 2011, Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours, Endocr Relat Cancer, 18, S27, 10.1530/ERC-10-0282

Rufini, 2012, Role of PET/CT in the functional imaging of endocrine pancreatic tumors, Abdom Imaging, 37, 1004, 10.1007/s00261-012-9871-9

Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, et al. 177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: results of the phase III NETTER-1 trial. Presented at: 2015 European Cancer Congress; September 25–29; Vienna, Austria. Abstract 6LBA.

Zaknun, 2013, The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours, Eur J Nucl Med Mol Imaging, 40, 800, 10.1007/s00259-012-2330-6

Poeppel, 2015, Peptide receptor radionuclide therapy for patients with somatostatin receptor expressing tumours. German Guideline (S1), Nuklearmedizin, 54, 1

Waldherr, 2002, Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC, J Nucl Med, 43, 610

Bodei, 2004, Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours, Eur J Nucl Med Mol Imaging, 31, 1038, 10.1007/s00259-004-1571-4

Valkema, 2006, Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3] octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors, Semin Nucl Med, 36, 147, 10.1053/j.semnuclmed.2006.01.001

Bushnell, 2010, 90Y-edotreotide for metastatic carcinoid refractory to octreotide, J Clin Oncol, 28, 1652, 10.1200/JCO.2009.22.8585

Imhof, 2011, Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers, J Clin Oncol, 29, 2416, 10.1200/JCO.2010.33.7873

Kwekkeboom, 2008, Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate: toxicity, efficacy, and survival, J Clin Oncol, 26, 2124, 10.1200/JCO.2007.15.2553

Bodei, 2011, Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I–II study, Eur J Nucl Med Mol Imaging, 38, 2125, 10.1007/s00259-011-1902-1

Ezziddin, 2014, Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate, J Nucl Med, 55, 183, 10.2967/jnumed.113.125336

Ezziddin, 2014, Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours, Eur J Nucl Med Mol Imaging, 41, 925, 10.1007/s00259-013-2677-3

Sabet, 2015, Specific efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumours of the small intestine, Eur J Nucl Med Mol Imaging, 10.1007/s00259-015-3041-6

Villard, 2012, Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers, J Clin Oncol, 30, 1100, 10.1200/JCO.2011.37.2151

Faivre, 2012, Updated overall survival (OS) analysis from a phase III study of sunitinib vs placebo in patients (pts) with advanced, unresectable pancreatic neuroendocrine tumors, ESMO Congress

Caplin, 2014, Lanreotide in metastatic enteropancreatic neuroendocrine tumors, N Engl J Med, 371, 224, 10.1056/NEJMoa1316158

Caplin, 2014, Progression-free survival (PFS) with lanreotide autogel/depot (LAN) in enteropancreatic NETs patients: the CLARINET extension study, J Clin Oncol, 32, 10.1200/jco.2014.32.15_suppl.4107

Phan, 2015, Effects of lanreotide autogel/depot (LAN) in pancreatic neuroendocrine tumors (pNETs): a subgroup analysis from the CLARINET study, J Clin Oncol, 32

Sabet, 2013, Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate, J Nucl Med, 54, 1857, 10.2967/jnumed.112.119347